Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

NCT03330405 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

223

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).

Conditions

Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors

Interventions

DRUG: Avelumab Phase 1b
DRUG: Talazoparib Phase 1b
DRUG: Avelumab Phase 2
DRUG: Talazoparib Phase 2

Sponsor

Pfizer